NCT03596502View on ClinicalTrials.gov

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

CompletedOBSERVATIONAL
Enrollment

402,764

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions
Atrial FibrillationIschemic StrokeSystemic EmbolizationMajor BleedMyocardial InfarctionAll-cause Mortality
Interventions
DRUG

Direct oral anticoagulants (DOACs)

Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.

DRUG

Warfarin

Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.

Trial Locations (1)

H2X 0A9

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal

All Listed Sponsors
collaborator

Drug Safety and Effectiveness Network, Canada

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Canadian Network for Observational Drug Effect Studies, CNODES

OTHER

NCT03596502 - Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin) | Biotech Hunter | Biotech Hunter